NOVOCURE ($NVCR) posted quarterly earnings results on Thursday, April 24th. The company reported earnings of -$0.31 per share, beating estimates of -$0.47 by $0.16. The company also reported revenue of $154,990,000, beating estimates of $149,536,375 by $5,453,625.
You can see Quiver Quantitative's $NVCR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVOCURE Insider Trading Activity
NOVOCURE insiders have traded $NVCR stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- FRANK X LEONARD (EVP, Pres., Novocure Oncology) has made 0 purchases and 4 sales selling 15,634 shares for an estimated $305,787.
- ASHLEY CORDOVA (Chief Executive Officer) has made 0 purchases and 3 sales selling 13,494 shares for an estimated $266,126.
- MUKUND PARAVASTHU (Chief Operating Officer) has made 0 purchases and 6 sales selling 4,378 shares for an estimated $100,868.
- URI WEINBERG (Chief Innovation Officer) has made 0 purchases and 2 sales selling 4,637 shares for an estimated $86,949.
- MICHAL NATH PURI (Chief Human Resources Officer) has made 0 purchases and 3 sales selling 2,197 shares for an estimated $40,564.
- NICOLAS LEUPIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 991 shares for an estimated $19,843.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NOVOCURE Hedge Fund Activity
We have seen 114 institutional investors add shares of NOVOCURE stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,739,704 shares (+inf%) to their portfolio in Q4 2024, for an estimated $81,643,179
- NORDWAND ADVISORS, LLC removed 2,717,669 shares (-89.7%) from their portfolio in Q4 2024, for an estimated $80,986,536
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,115,692 shares (-39.8%) from their portfolio in Q4 2024, for an estimated $33,247,621
- CAPITAL INTERNATIONAL INVESTORS added 951,141 shares (+12.0%) to their portfolio in Q4 2024, for an estimated $28,344,001
- GRANITE INVESTMENT PARTNERS, LLC added 686,727 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,464,464
- PRICE T ROWE ASSOCIATES INC /MD/ removed 638,378 shares (-27.5%) from their portfolio in Q4 2024, for an estimated $19,023,664
- EMERALD ADVISERS, LLC added 547,557 shares (+inf%) to their portfolio in Q4 2024, for an estimated $16,317,198
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NOVOCURE Government Contracts
We have seen $10,453,169 of award payments to $NVCR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETICS: $149,246
- TRANSDUCER: $99,497
- PROSTHETIC: OPTUNE PLUS TRANSDUCERS: $99,497
- OPTUNE TRANSDUCERS 3 MONTH RENTAL: $99,497
- PROSTHETICS. OPTUNE PLUS TRANSDUCER.: $99,497
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NOVOCURE Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI issued a "Outperform" rating on 01/02/2025
- H.C. Wainwright issued a "Buy" rating on 10/31/2024
To track analyst ratings and price targets for NOVOCURE, check out Quiver Quantitative's $NVCR forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
